Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.92% 7.65 7.50 7.80 7.80 7.55 7.80 939,218 10:37:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 21

Evgen Pharma Share Discussion Threads

Showing 7926 to 7946 of 8375 messages
Chat Pages: Latest  323  322  321  320  319  318  317  316  315  314  313  312  Older
DateSubjectAuthorDiscuss
27/3/2021
22:29
Oh yes amaretto who deramps STX where directors have invested millions of pounds ..currently 33p will be over 100pAnd amaretto Ramps evg where directors bought 300 quid of stock ..will be 2pI can't wait to dump my evg The directors are a disgrace
nico115
27/3/2021
21:27
I used to hold some Evgen shares in the past. My two cents.... the company tends to bite a little more than it can chew. The indications it has focused on:- breast cancer, COVID, SAH (in past)... these indications need lots of $$$$. Not easy to get a drug approved in these disease areas, even for big Pharma. Look at Reata with their NRF-2 inhibitors...being developed successfully for orphan diseases. I don’t think Evgen has had very experienced medical/scientific leadership, with knowledge to bring these drug assets across the line. In the recent fund raise, I would have targeted £20 million. Anyway, my humble opinion.
diamondstar1
27/3/2021
21:16
Some decent names on the share register there & certainly been some churn at the ii level over the last 12 months. Let’s hope that transition phase is ending and similarly the transition in business model will now start to bear fruit.
bumpa33
27/3/2021
21:09
httPs://www.wsj.com/articles/covid-19-variant-rages-in-brazil-posing-global-risk-11616845889?redirect=amp#click=hxxps://t.co/Af1EIwanBo makes for chastening reading...
bumpa33
27/3/2021
19:36
Succinct and to the point Amaretto
bocker01
27/3/2021
18:19
Where did that short thread come from? Are they nuts?
notknowing
27/3/2021
18:08
Thx I'm a seller now Unless Helen buys Let's see
nico115
27/3/2021
17:35
Thanks OT.
the millipede
27/3/2021
15:17
He still hasn't resurfaced as far as I know,but good luck to him regardless and I think he ended up with over 4.5m shares and so no doubt would be prudent if he had kept a few for Evgen's "next stage" and true and substantial value. As far as the new new high quality investors and existing Major shareholders are concerned who participated in the £10m placing, I wouldn't be surprised if they had been given access to some of the data on the breast cancer programme and other targets yet to be made public as well as the compelling data on glioma/glioblastoma, we also know that Octopus has a strong connection with Jim Mellon which could have had some sway....anyways, looking forward to Q2 with great excitement and anticipation to see what Huw has to report. Gla :')
moneymunch
27/3/2021
14:52
This is what he posted on his linkedin account at the time: "Taking time out Hi all - I have been inundated with calls and messages since yesterday's announcement, so I thought I would make a short post on my personal Linked-In account. Deciding to leave Evgen was a tough call, but one that I made in the best interests of the shareholders. The share price has been suppressed for a while and does not reflect the true and substantial value in the business. What is needed now is fresh vision and new energy to take it to the next stage. The Company remains a great business and I will continue to support them as a long-term shareholder. I intend to take a short break now to recharge and will resurface in due course. Thank you to all those that have sent kind messages at this time of change."
on target
27/3/2021
14:26
The directors' very modest holdings and their tiny top-ups in the recent placing are annoying, and I'd also like them to put some decent money in. However, you can't ignore the fact that EVG is well backed by quality institutional investors, especially so in the recent placing. It gives plenty of reassurance that there isn't 'something up' that these guys saw fit to invest millions earlier this month: Major shareholder Number of shares Percentage holding AXA Framlington 23,848,884 8.7% Octopus Investments 21,875,000 8.0% SPARK Impact 16,186,446 5.9% Seneca Investment Managers 14,932,071 5.4% Chelverton Asset Management 12,500,000 4.5% RAB Capital 8,750,000 3.2% Newlands Capital 8,314,815 3.0% These guys aren't bucket shops and neither are they mug punters.
on target
27/3/2021
13:53
And if the directors were onlyLookingFor 3 to 5m why did they raise 10m ? Maybe they aren't confident of decent trial results ?I bought a chunk at 8p but now seriouslyConsidering dumping them Director buys or lack of them worries me
nico115
27/3/2021
13:29
The former CEO had quite a lot of shares, but he might have sold. Anyone have any idea why he left? (Beyond what was written in the RNS.)
the millipede
27/3/2021
13:05
The directors' very modest holdings and their tiny top-ups in the recent placing are annoying, and I'd very much like them to put some decent money in. However, you can't ignore the fact that EVG is well backed by quality institutional investors, especially in the recent placing. It gives plenty of reassurance that there isn't 'something up' that these guys saw fit to invest millions earlier this month: Major shareholder Number of shares Percentage holding AXA Framlington 23,848,884 8.7% Octopus Investments 21,875,000 8.0% SPARK Impact 16,186,446 5.9% Seneca Investment Managers 14,932,071 5.4% Chelverton Asset Management 12,500,000 4.5% RAB Capital 8,750,000 3.2% Newlands Capital 8,314,815 3.0%
on target
27/3/2021
11:20
No money munch Octopus bought a chunk of Verditek at 8p and have halved their money I rather back directors Oh 3k shares bought This is poo
nico115
27/3/2021
09:57
Maybe he should be voicing his concerns to the UK's leading and most powerful VC group, who have just invested £1.75m in Evgen, along with Chelverton Assest Management's £1m and RAB Capiatl's £700k as well as AXA inreasing their holding by another £1m plus and Seneca by £750k, a supreme show of confidence in Evgen's prospects and potential going forward, fully funded until mid 2023 with multiple shots on multiple targets. Gla Holders....news on Prof Chalmers preliminary efficacy assessment from SFX-01's Covid/ARDS patient trials coming soon, positive data will be very well received. ;-) March 2021 Event Voice: Your Questions Answered by Octopus Investments at Investment Select Richard Power, Head of Quoted Smaller Companies at Octopus Investments Can you give a brief overview of your strategy in terms of what you are trying to achieve for investors, your investment process and the make-up of the investment team? The lead manager of the fund is Richard Power, who has been running the fund since its launch in 2007. Richard is directly assisted by Chris McVey and Dominic Weller in addition to the wider Quoted Companies Team at Octopus which consists of 8 investment professionals. The team manage a range of mandates focused on quoted smaller companies, including two AIM Venture Capital Trusts which ensures a good focus on, and understanding of, the smallest quoted companies. Collectively, the team manage £2.2bn. We invest in small, relatively early-stage businesses. These micro cap companies tend to be sub-100 million. In general, we're looking for companies that can become relevant in their particular sector on a global scale and have the potential to grow to a multiple of the size they are at the point of investment. Our philosophy is to become long-term co-owners in businesses that are very progressive and will become increasingly relevant in the world. We won't do what some other micro-cap funds might do, which is sell when companies get to a certain market cap. We'll continue to hold them until we think that they have reached a point where all of the upside is in the share price. That means we've got a core portfolio of companies that are profitable and on a recognisable growth trajectory. We hope those businesses can double their profits in a three to five-year time horizon. A lot of our holdings have been in the portfolio for ten years and have gone up ten, 15 or 20-fold in that time. hTtps://www.investmentweek.co.uk/sponsored/4027908/event-voice-questions-answered-octopus-investments-investment-select
moneymunch
26/3/2021
22:54
Great news Wow strong confidence by the CFO5 March 2021Evgen Pharma plc("Evgen Pharma" or "the Company")Director dealingEvgen Pharma plc (AIM: EVG), a clinical stage drug development company, has been notified that Richard Moulson, Chief Financial Officer of the Company, has purchased 3,787 ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") at a purchase price of 8 pence per Ordinary Share, as part of the Open Offer in the recent Fundraise. Following this purchase, Richard Moulson holds a total of 45,454 Ordinary Shares, representing approximately 0.02 per cent. of the Company's issued share capital.Enquiries:
nico115
26/3/2021
21:42
Haha says AmerettoSo you deramp STX where directors keep buying And ramp evg WHERE DIRECTORS REFUSE TO BUY I THINK EVG WILL BE 2p and STX 100pI hold both but much larger In STX I may DUMP my evg Why should I keep when directors here hold no shares
nico115
26/3/2021
21:40
You get a life mate You post hundreds of times a day V sad existence Directors refuse to buy They are on a freebie They laugh at your posts Is they aren't confident why are you ?
nico115
26/3/2021
21:30
nico's got his coat and gone...:-)
moneymunch
26/3/2021
20:52
Lol...get a life you little dipstick...ho ho ho :-)
moneymunch
Chat Pages: Latest  323  322  321  320  319  318  317  316  315  314  313  312  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210513 03:42:01